Pulse Biosciences, Inc. (PLSE)
NASDAQ: PLSE · Real-Time Price · USD
15.08
+0.55 (3.79%)
At close: Apr 4, 2025, 4:00 PM
15.96
+0.88 (5.82%)
After-hours: Apr 4, 2025, 7:56 PM EDT
Company Description
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company.
The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.
The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015.
Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Miami, Florida.
Pulse Biosciences, Inc.
| Country | United States |
| Founded | 2014 |
| IPO Date | May 18, 2016 |
| Industry | Medical Instruments & Supplies |
| Sector | Healthcare |
| Employees | 56 |
| CEO | Paul LaViolette |
Contact Details
Address: 601 Brickell Key Drive, Suite 1080 Miami, Florida 33131 United States | |
| Phone | 510 906 4600 |
| Website | pulsebiosciences.com |
Stock Details
| Ticker Symbol | PLSE |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001625101 |
| CUSIP Number | 74587B101 |
| ISIN Number | US74587B1017 |
| Employer ID | 46-5696597 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Paul Arthur LaViolette | President, Chief Executive Officer, Principal Executive Officer, Principal Financial Officer and Co-Chairman of the Board |
| Robert W. Duggan | Executive Co-Chairman |
| Darrin R. Uecker | Chief Technology Officer and Director |
| Mitchell E. Levinson | Chief Strategy Officer |
| Kevin P. Danahy | Chief Commercial Officer and Principal Executive Officer |
| Jon Skinner | Chief Financial Officer |
| Edison Manuel | Vice President of Operations |
| Dr. Richard Nuccitelli Ph.D. | Chief Science Officer |
| Kenneth B. Stratton Esq., J.D. | General Counsel and Corporate Secretary |
| Patty Perla | Vice President of Human Resources |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 31, 2025 | 10-K | Annual Report |
| Mar 28, 2025 | 8-K | Current Report |
| Feb 27, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 27, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 4, 2025 | 8-K | Current Report |
| Jan 23, 2025 | 8-K | Current Report |
| Jan 14, 2025 | 8-K | Current Report |
| Jan 13, 2025 | 8-K | Current Report |
| Dec 26, 2024 | 8-K | Current Report |
| Dec 19, 2024 | SCHEDULE 13D/A | Filing |